Fundraising Fox
Cambridge · Seed–Series B · 84 people tracked
Also known as ATLAS VENTURE ADVISORS, INC. · ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Find your way into Atlas Venture
Sign up to see every warm intro you have to Atlas Venture
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atlas Venture team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Atlas Venture focuses on medical and biotech innovation, backing early-stage life sciences companies. The firm operates an incubator through which it launches new startups, and its portfolio companies have developed approved medicines and achieved outcomes including IPOs and M&A exits. With roughly thirty years of experience, the firm positions itself at the leading edge of medical innovation.
Source: firm website, verified Sep 29, 2026.
Team · 84 people
from the firm's website & curated & public directories
Founder mafia
The Atlas Venture mafia →40 people who came through Atlas Venture went on to found or lead other companies.
What they invest in
from 118 of 169 portfolio companiesBiotech ×81Healthtech ×54Medical Devices ×22Deep Tech ×16AI & Machine Learning ×15Digital Health ×8SaaS ×8Enterprise Software ×6
HQs:United States×100United Kingdom×3Canada×2Azerbaijan×1Iceland×1Luxembourg×1
Who they back
founder profiles across 23 portfolio companiesFounding team size:solo founder×72 founders×93 founders×34+ founders×4
Where their founders studiedfrom 14 founders with education data
Columbia University ×2Imperial College London ×2
What their founders studiedfrom 12 founders with field-of-study data
Chemistry ×4Life Sciences ×4Medicine ×4
Where their founders worked beforefrom 19 founders with career history
Massachusetts General Hospital ×2Omega Funds ×2RaNA Therapeutics ×2Scorpion Therapeutics ×2Vectura Group plc. ×2
backed the same founder in 2+ companies: 2 founders
Investments · 169 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 72024 · 112023 · 72022 · 62021 · 92020 · 62019 · 72018 · 82017 · 42016 · 42015 · 11110 dated
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures5AM Ventures+2 more
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsOrbiMedRA CapitalViking Global
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Board seatKevin Bitterman· per SEC Form D · $120M raise · filed Aug 2015
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalDeerfield Management CompanyFlagship Ventures+2 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Board seatJean-François Formela· per SEC Form D
Co-investorsage1Avoro Capital AdvisorsEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+1 more
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Board seatKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015
Co-investorsLongitude CapitalSR One Capital ManagementWellington ManagementYsios CapitalLux CapitalRA Capital+1 more
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in
Board seatJean-François Formela· per SEC Form D
Co-investorsMC Healthcare VenturesNew Enterprise Associates (NEA)AlexandriaQiming Venture PartnersQiming Venture Partners USARock Springs Capital+3 more
Neuronetics manufactures and sells the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation device used in office-based treatment of major depressive disorder and other mental health conditions, along with operating a network of treatment centers that provide both NeuroStar therapy and esketamine treatment to patients.
HealthtechMalvern, US
Mark R. Bausinger(Executive Officer)inChristopher Thatcher(Executive Officer, Director)inDaniel L. Reuvers(President and Chief Executive Officer)
BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)
Board seatKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015
Co-investors1315 CapitalAscension VenturesCHV CapitalGE Ventures
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Board seatJean-François Formela· per SEC Form D
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)RA CapitalAlphabet+1 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical DevicesCambridge, US
John Maraganore(Founder)inPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)
Co-investorsARCH Venture PartnersBlackstone Life SciencesCardinal PartnersInvivo Capital PartnersAlexandria
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundLongwood FundRidgeback Capital+4 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+7 more
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsMPM BioImpactVida VenturesWellington ManagementForbionHercules Capital, Inc.RA Capital
Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types.
BiotechHealthtechSan Francisco Bay Area, US
Michael M. Morrissey(President and Chief Executive Officer)inChristopher J. Senner(Executive Vice President and Chief Financial Officer)
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson IJoaquin DuatoinJ. Duato(Chief Executive Officer)
Co-investorsAisling CapitalNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column GroupvenBio Partners
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+7 more
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBrace PharmaBroadview VenturesMC Healthcare VenturesRidgeback CapitalBoulder VenturesHeartland+1 more
Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.
BiotechHealthtechMedical Devices
Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)
Co-investorsBain Capital Life SciencesForesite CapitalREDMILE
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPaul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in
Co-investorsCLI VenturesNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSofinnova VenturesSolasta Ventures+1 more
Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.
BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US
Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)inAndrew Robbins(Chief Executive Officer, President and Director)inJohn Green(Chief Financial Officer)inEvan Kearns(Chief Legal Officer and Corporate Secretary)inCole Pinnow(Chief Commercial Officer)in
Co-investorsF-Prime CapitalSanofi Ventures
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
Board seatJean-François Formela· per SEC Form D
Co-investorsLightspeed Venture PartnersVida VenturesOmega FundsTenmileAbingworthAlleyCorp+1 more
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)
BoardBrendan Bulik-Sullivan(Director)in
Board seatDavid Grayzel· per SEC Form D
Co-investorsGV (Google Ventures)Broadview VenturesF-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)
IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.
BiotechHealthtechCambridge, US
Gary D. Glick(Founder)inH. Martin Seidel(Chief Executive Officer)in
BoardJean-Francois Formela(Director)in
Board seatJean-François Formela· per SEC Form D
Co-investorsAbingworth
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Board seatKevin Bitterman· per SEC Form D
Co-investors5AM VenturesRA CapitalEQT Life SciencesGimvSixty Degree CapitalVivo Capital+3 more
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatKevin Bitterman· per SEC Form D
Co-investorsForesite CapitalThe Column GroupARCH Venture PartnersAlexandriaDecheng Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Board seatDavid Grayzel· per SEC Form D
Co-investorsAscenta CapitalLightspeed Venture PartnersRA CapitalBessemer Venture PartnersPfizer VenturesFinchley Healthcare Ventures+3 more
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsJanus Henderson InvestorsLAVvenBio PartnersWellington Management
Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.
BiotechHealthtechMedical DevicesLondon, GB
Dr Jeff Moore(Founder & CEO)
Co-investorsBiotechnology Value FundCanaan PartnersProspect Venture PartnersOxford Technology Management
Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.
BiotechHealthtechCambridge, US
Niranjan Kameswaran(Chief Executive Officer)inJessica Stromme(Chief Development Officer)inKelly Foster(Chief Scientific Officer)inStephen Huang(Senior Vice President, Head of Clinical Development)in
BoardSimon Read(Chairman of the Board and Independent Board Member)in
Co-investorsAvoro Capital AdvisorsMedicxi
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Judo Bio Co-Founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(Executive Chair and Acting CEO)inWilliam Ho
Co-investorsDigitalis VenturesDroia VenturesThe Column GroupYK Bioventures
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersSanofi Ventures5AM Ventures
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+11 more
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsBiotechnology Value FundForbionLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)
Co-investorsDC Investment PartnersLongwood FundForbion
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)inJudy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)inAriel D. Jasie(Chief Business Officer and General Counsel)inTushar Misra(Chief Technical Officer)in
Co-investorsFrazier Life SciencesAccess IndustriesAccess BiotechnologyCanaan Partners
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Board seatDavid Grayzel· per SEC Form D
Co-investorsEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover
nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies.
BiotechLongevityBoston, US
Angelo Lombardo(Founder)David R. Liu(Founder)J. Keith Joung(Founder)Jonathan S. Weissman(Founder)Luigi Naldini(Founder)Luke Gilbert(Founder)
Board seatKevin Bitterman· per SEC Form D · $135M raise · filed Sep 2023
Co-investorsOUP (Osage University Partners)Wellington ManagementCasdin CapitalGV (Google Ventures)Newpath Partners
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)inDaniel Becker(Director)
Board seatMichael Gladstone· per SEC Form D
Co-investorsAccess BiotechnologyCanaan PartnersViking GlobalAccess IndustriesRA CapitalThe Column Group
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.
BiotechDeep TechHealthtechCambridge, US
Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024
Co-investorsLeaps by BayerREDMILEAlumni VenturesDigitalis VenturesDreamers VCRising Tide+3 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Board seatKevin BittermanJean-François Formela· per SEC Form D
Co-investorsage1Brace PharmaSanofi VenturesPolaris PartnersSR One Capital Management
BiotechCambridge, US
Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)
BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)
Board seatJean-François Formela· per SEC Form D
Co-investorsPfizer Venture Investments
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)inEmily Conley(Executive Officer, Director)in
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Board seatKevin Bitterman· per SEC Form D
Co-investors5AM VenturesOrbiMedQiming Venture PartnersQiming Venture Partners USA
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatJean-François Formela· per SEC Form D
Co-investorsAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Co-investorsNeva Sgr.Sofinnova PartnersXGEN VentureForbionLongwood Fund
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsBain Capital Life SciencesRA CapitalSofinnova VenturesForbion
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsForesite CapitalFrazier Life SciencesLifeSci Venture PartnersScion Life SciencesThe Innovation SpacevenBio Partners+1 more
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsMission BiocapitalPfizer Venture InvestmentsPfizer VenturesPivotal Life Sciences
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to Cures+6 more
Become provides a technology platform that matches small and medium-sized businesses with tailored funding options using advanced algorithms.
FintechMarketplacesSaaS
Co-investorsEntrée Capital
Bluespec develops tools and IP for hardware and embedded systems developers, with a focus on RISC-V technology for core evaluation, software development, acceleration, and verification.
Deep TechDeveloper ToolsHardwareSemiconductorsFramingham, US
Arvind Mithal(Director)Charles Hauck, Jr.(Executive Officer, Director)Paul Pedevillano(Executive Officer)inCharlie Hauck(Chief Executive Officer)inBrian McAloon(Director)Dave Lemont(Director)in
Co-investorsAccompliceNorth Bridge Venture Partners & Growth Equity
The site presents a multi-day conference about application and web design, covering design theory, tools, product design roles, and current web design trends.
Media & Entertainment
Co-investorsBantam GroupBoston Seed CapitalLaunchCapital
Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Co-investorsQiming Venture Partners USASlater Technology FundAccess IndustriesClal Biotechnology IndustriesCowen Healthcare InvestmentsNovartis Institute for Biomedical Research+1 more
Waltham, US
Patrick Morley(Executive Officer, Director)inEric Pyenson(Executive Officer)Gordon Pothier(Executive Officer)Ben Johnson(Founder)Michael Viscuso(Founder)
BoardRonald Nordin(Director)
Co-investors.406 VenturesAccompliceAgman PartnersEvolution Equity PartnersFounders Circle CapitalIntel Capital+6 more
Chill.com publishes wellness content focused on stress, recovery, sleep, and gut health, with references to supplements for supporting the body under sustained stress.
ConsumerImpact & Social GoodMedia & EntertainmentWellness & Fitness
Brian NorgardDan Gould
Co-investors500 GlobalKleiner PerkinsLowercase CapitalRedpoint Ventures
Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.
Cloud ComputingEnterprise SoftwareNew York, US
Co-investorsMatrixNorth Atlantic CapitalNorwest Venture Partners
Advertising technology platform providing audience-based sales for television advertising.
Somerville, US
Joshua Summers(Executive Officer, Director, Promoter)Doug Hurd(Executive Officer, Director, Promoter)
BoardRyan Moore(Director)Lars Albright(Director)in
Co-investorsBoston Seed CapitalTransmedia CapitalTribeca Venture PartnersData Point CapitalFreestyle CapitalWestern Technology Investment
A marketplace where independent designers sell digital assets such as fonts, graphics, templates, photos, and themes to other creators.
Developer ToolsEnterprise SoftwareMarketplacesSan Francisco, US
Darius "Bubs" Monsef(Founder)inAaron Epstein(Founder)inChris Williams(Founder)inChris Winn(Executive Officer, Director)in
BoardCack Wilhelm(Director)
Co-investors500 GlobalFounder CollectiveOnStartupsY CombinatorAccompliceAlexis Ohanian+17 more
CustomMade is a custom jewelry design and creation service that works with clients to create bespoke pieces, including bridal, heirloom redesign, and fine jewelry.
B2B MarketplacesConsumerDirect to ConsumerE-commerceDover, US
Seth Rosen(Executive Officer, Director)in
BoardDavid Hauser(Director)Sasha Shusteff(Director)
Co-investorsNextView VenturesWestern Technology InvestmentFirst Round CapitalFounder CollectiveGV (Google Ventures)Launch Capital+1 more
deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.
AI & Machine LearningBiotechDeep TechReykjavik, IS
Kári Stefánsson(Founder)in
Co-investorsARCH Venture Partners
DeepScale developed efficient deep neural network software for perception systems in autonomous vehicles, optimized to run on low-power automotive-grade processors.
Mountain View, US
Sri Chandrasekar(Director)Forrest Iandola(Executive Officer, Director)Kurt Keutzer(Director)
Co-investorsAutotech VenturesNext47Trucks VC11.2 CapitalCota Capital
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Alex Lugovskoy(Founder)Michael Gladstone(Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesRA CapitalRV Invest GmbHSanofi VenturesViking Global
DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.
Enterprise SoftwareHardwareSemiconductors
Martin King(Founder)Quentin Stafford-Fraser(Founder)
Co-investorsBalderton CapitalDag VenturesCipio PartnersPrelude Ventures
Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.
AgTechBiotechRantoul, US
Eddy Mejia(Co-founder)inDr. Gabe Price(Co-founder)
Co-investorsAg Ventures AllianceAgLaunch AcceleratorBoot64 VenturesAdams Street PartnersAndreessen HorowitzBattery Ventures+4 more
Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products.
BiotechHealthtechMedical DevicesWayne, US
BARBARA A. CARLIN(SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER)ROBERT S. RADIE(CHIEF EXECUTIVE OFFICER)MARK STROBECK(EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER)MEGAN TIMMINS(SENIOR VICE PRESIDENT AND GENERAL COUNSEL)PATRICK M. SHEA(SENIOR VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER)Jeffrey M. Dayno(Chief Medical Officer)
Co-investorsSunstone Capital
EnglishCentral is an online English language learning platform offering videos and courses for learners.
AI & Machine LearningEdTechSaaS
Alan Schwartz(Founder & CEO)inIan Park(President & Board Member)
Co-investorsBantam GroupValor Capital Group
Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)in
BoardJean George(Director)Jason Rhodes(Director)inCarl Gordon(Director)in
Co-investorsAltium CapitalLightstone VenturesOrbiMed
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsForesite CapitalWellington ManagementCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more
Advanced ManufacturingDeep TechFintechHardwareSaaSCambridge, US
Indrek Narusk(Founder)inHardi Meybaum(Founder)in
BoardDavid Skok(Director)in
Co-investorsAsimov VenturesHeuristic Capital PartnersMatrixNextView VenturesTechstarsTera Ventures
Stratasys develops polymer 3D printing systems and software for product design, prototyping, and manufacturing across aerospace, automotive, healthcare, and other industries.
Advanced ManufacturingHardwareNew Materials
Co-investorsLerer HippeauMatrixNextView Ventures
Influencer marketing platform connecting brands with social content creators for performance-measured, whitelisted paid social campaigns.
Cambridge, US
Brendan Lattrell(Executive Officer, Director)
BoardDavid Balter(Director)
Co-investorsBantam GroupKae CapitalRiverwalk HoldingsTechstars
Grapevine operates a platform for Giving Circles that enables groups to pool donations, manage members, and direct funds to nonprofits.
Impact & Social GoodSaaSSocial
Emily RasmusseninJessan Hutchinson-Quillian
Co-investorsDiagram CapitalKae CapitalNotation CapitalOverton Venture CapitalPJCUlu Ventures+2 more
Grapevine builds software that acts as a purchasing agent for healthcare buyers, comparing vendors, prices, and supply routes in real time to lower the cost of medical supplies.
B2B MarketplacesDigital HealthHealthtechLogistics & Supply ChainSaaSNew York, US
Luká Yancopoulos(CEO & Co-Founder)in
Co-investorsThe MBA FundPeak XV Partners
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners5AM Ventures8VCPanacea VentureTaiho Ventures, LLCTakeda Ventures
Travel technology company partnered with Capital One Travel.
Montreal
Frederic Lalonde(Founder)Joost Ouwerkerk(Founder)
Co-investorsAccompliceAgman PartnersBrightspark VenturesCapital One VenturesDream Maker VenturesDrive Capital+11 more
Amgen is a pioneer in biologic medicine development using living cells to create treatments for serious illnesses with limited existing options.
BiotechHealthtech
Co-investorsAvoro Capital AdvisorsNew Enterprise Associates (NEA)
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsB Capital GroupB4 CapitalMRL Ventures FundPivotal Life SciencesSofinnova PartnersSolasta Ventures+2 more
.jpeg){kind=logo}
IFM is an investment manager focused on long-term value creation across listed and non-listed assets, emphasizing sustainable competitiveness and stakeholder value alongside financial returns.
FintechSector AgnosticLuxembourg, LU
Co-investorsInterogo Holding AG
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.
BiotechHealthtechSan Diego, US
Co-investorsOrbiMed
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalHM Venture PartnersOUP (Osage University Partners)Sanderling VenturesSanofi VenturesSPRINGROCK VENTURES+4 more
Influitive provides a SaaS platform and professional services for customer advocate marketing, helping companies discover and mobilize their customer advocates to drive sales and customer lifetime value.
Marketing TechMedia & EntertainmentSaaS
Mark Organ(Founder)inPuneet ArorainRich Stollerin
Co-investors500 GlobalExtreme Venture PartnersExtreme Venture Partners LLPGolden VenturesHummer Winblad Venture Partners (HWVP)Illuminate Ventures+8 more
Integral Ad Science provides advertising verification and quality assurance solutions for digital advertisers and platforms.
AdTechAI & Machine LearningData & InfrastructureMarketing TechNew York, US
Lidiane Jones(Chief Executive Officer)inAmit Chaturvedi(Chief Operating Officer)inSrishti Gupta(Chief Product Officer)inThomas Joseph(Chief Technology Officer)inLisa Nadler(Chief Human Resources Officer)inYossi Almani(Chief Legal Officer)in
Co-investorsAccompliceAugust CapitalCross Creek AdvisorsFounder CollectiveGolub GrowthLobby Capital+6 more
JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.
Digital HealthHealthtechMedical DevicesIrvine, US
Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)
.jpg)
BoardArnd Kaltofen(Director)inErik Amble(Director)
Co-investorsAndera PartnersBain Capital Life SciencesRosetta Capital Ltd.VI PartnersGimvInnovatus Capital Partners+5 more
A biotechnology company developing cancer therapies for patients with unmet medical needs.
BiotechHealthtech
Co-investorsF-Prime CapitalNextech InvestEight Roads Ventures
Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.
BiotechHealthtechMedical Devices
Co-investorsBain Capital Life SciencesCatalio Capital Management, LP
Cambridge, US
Sravish Sridhar(Executive Officer, Director)in
BoardFrank Castellucci(Director)Braden Bohrmann(Director)William Burnham(Director)Jon Karlen(Director)Brady Bohrmann(Director)
Co-investorsAvalon Ventures Management, LlcBantam GroupNTT DOCOMO VenturesTechstarsVerizon Ventures
Lagoa is a Canadian company that runs a cloud-based platform for creating and rendering 3D content.
Construction Tech
Arno ZinkeDov AmihodThiago Costa
Co-investors500 GlobalRho Ventures
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsSanofi VenturesHatteras Venture PartnersLilly VenturesOmega FundsRoche Venture Fund
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAccess BiotechnologyNextech InvestAccess IndustriesForbionRA Capital
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologyDigitalis VenturesSanofi VenturesAccess IndustriesAlexandria
Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.
AI & Machine LearningBiotechDeep Tech
Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)
Co-investorsSanofi VenturesDigitalis Ventures
BiotechHealthtech
Jean-Paul Kress, M.D.in
Co-investorsBayern KapitalRidgeback Capital
Plastiq enables businesses to pay vendors using credit cards while vendors receive payments via wire, ACH, check, or other methods, combined with embedded payment processing and card acceptance solutions for merchant transactions.
FintechSan Francisco, US
Eliot Buchanan(Executive Officer, Director)inDaniel Choi(Executive Officer)inGeoffrey Willison(Executive Officer)inMichail Medvinsky(Executive Officer)in
BoardRyan Moore(Director)Jeffrey Bussgang(Director)in
Co-investorsAcorn Pacific VenturesBling CapitalFlybridge Capital PartnersParade VenturesSocii CapitalAccomplice+5 more
Advanced ManufacturingMobility & TransportationAnn Arbor, US
Lihang Nong(Founder)inErik Kauppi(CTO)Parke Wiegman(Manager)
Co-investorsY CombinatorAdditionBackend CapitalConscience VCCory LevyEmerging Ventures+4 more
Nimbus provides automated cost optimization for Datadog customers, reducing their observability expenses without requiring manual intervention from engineering teams.
AI & Machine LearningData & InfrastructureEnterprise SoftwareSeattle, US
Kevin Lin(Founder)inBernhard Echte(Founder)Lihang Nong(Founder)inKiran Pathakota(COO)
Co-investorsY CombinatorAltaclub VCAltaIR CapitalCommunity Access FundFirst Rays Venture PartnersFoothill Ventures+4 more
HireNimbus is a mobile platform that connects homeowners with vetted local home service professionals for booking, payment, and job tracking.
AI & Machine LearningFintechImpact & Social GoodMarketplacesPropTechSaaSAlexandria, US
Satadru Sengupta(Founder)in
Co-investorsSamvid VenturesTechstarsGV (Google Ventures)
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyBain Capital Life SciencesBiotechnology Value FundCommodore CapitalGV (Google Ventures)+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyBain Capital Life SciencesBiotechnology Value FundCommodore Capital+3 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone VenturesPfizer Venture Investments+4 more
NxStage provides home dialysis products and support for people with chronic kidney disease and end-stage renal disease, including home hemodialysis and peritoneal dialysis.
Digital HealthHardwareHealthtechMedical DevicesLawrence, US
Co-investorsCross Creek AdvisorsLongitude CapitalAdams Street PartnersLightspeed Venture Partners
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)inTom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)inParameswaran Hari(Chief Medical Officer)inJulie Feder(Chief Financial Officer)inDana Alexander(Chief Technical Officer)in
Co-investorsTCG CrossoverVertex Ventures HCWellington Management
PillPack is a full-service pharmacy that organizes and delivers medications to customers, managing automatic refills and coordinating directly with doctors and insurance providers.
Digital HealthHealthtechManchester, US
Timothy Parker(Chief Executive Officer, Director)inElliot Cohen(Chief Technology Officer, Director)inTJ Parker(Founder)in
BoardDavid Frankel(Director)inJon Karlen(Director)Fred Destin(Director)
Co-investorsAccelAccompliceACME CapitalBoxGroupCRV (Charles River Ventures)Entrée Capital+12 more
Digital banking and financial services for small businesses
Daniel Choi(Founder)Eliot Buchanan(Founder)
Co-investorsAccompliceAcorn Pacific VenturesAlumni VenturesBling CapitalFirebolt Ventures Management Company, LlcFJ Labs+7 more
Recorded Future provides cyberthreat intelligence and AI-powered cyber defense capabilities to help organizations identify and neutralize critical threats.
AI & Machine LearningCybersecurityData & InfrastructureEnterprise SoftwareSomerville, US
Christopher Ahlberg(Founder)inStaffan Truve(Director)Staffan Truvé(Founder)
BoardLiautaud Bernard(Director)Rich Miner(Director)inJeff Fagnan(Director)
Co-investorsAccompliceBalderton CapitalBaukunstGula Tech AdventuresGV (Google Ventures)In-Q-Tel+4 more
HealthtechCambridge, US
Adam Rosenberg(Executive Officer, Director)inAnkit Mahadevia(Founder)in
BoardBruce Booth(Director)inKees Been(Director)Samantha Singer(Director)
Co-investorsGV (Google Ventures)Hatteras Venture PartnersThird Point VenturesJJDCRemeditex Ventures
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
New York, US
Edward Kim(Executive Officer, Director)Kent Krekorian(Executive Officer)inHal Muchnick(Executive Officer, Director)in
BoardBo Peabody(Director)Benjamin Sun(Director)Kirk Wolfe(Director)in
Co-investorsMI VenturesSocial StartsMK CapitalSpring Mountain Capital
Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps.
BiotechHealthtechCambridge, US
Co-investorsHEALTHCARE ROYALTY PARTNERSThe Kraft Group
Sqrrl was a Cambridge, Massachusetts cybersecurity startup that built a threat-hunting platform based on Apache Accumulo, an NSA-derived big-data database technology, to help enterprises detect and investigate cyber threats.
Cambridge, US
Adam Fuchs(Executive Officer)Ely Kahn(Executive Officer, Director)Mark Terenzoni(Executive Officer, Director)Jeff Williams(Director)
BoardAntonio Rodriguez(Director)inZenas Hutcheson(Director)in
Co-investorsAlumni VenturesRally Ventures Management, LlcMatrix
Co-investorsBain Capital Life SciencesOrbiMed
Trace Neuroscience is a biotech company developing genetic medicines that restore UNC13A protein function to treat amyotrophic lateral sclerosis (ALS), with a lead antisense oligonucleotide program targeting UNC13A mRNA splicing.
BiotechHealthtech
Pietro Fratta(Scientific Co-founder)
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Co-investorsAscenta CapitalBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedViking Global+4 more
FintechBoston, US
Co-investorsBantam GroupGV (Google Ventures)TechstarsBoston Seed CapitalCounterview Capital
Co-investorsTCG CrossoverAditum Bio
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Co-investorsLightstone VenturesPivotal Life SciencesVida VenturesHatteras Venture PartnersLongwood Fund
Vurb is a mobile search app that lets people find, save, and act on recommendations for things like travel, entertainment, and dining by combining community suggestions, content, and services in one app.
ConsumerMedia & EntertainmentMobility & TransportationSocialSan Francisco, US
Co-investorsRedpoint VenturesVivi NevoDCVC (Data Collective)TenOneTen VenturesStanford UniversityTuesday Capital
Wedding Spot is an online marketplace where couples can search, compare, and book wedding venues across the United States based on budget, location, style, and guest count.
ConsumerMarketplacesTravel & HospitalitySan Francisco, US
Tina Hoang-To(Executive Officer, Director)
Co-investorsCanyon Creek CapitalGreat Oaks Venture CapitalKEC VenturesMAIDEN LANE
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aerovate Therapeutics, Inc.Akero Therapeutics, Inc.Akriveia TherapeuticsAmagma, Inc.Antegrin TherapeuticsCaldera Therapeutics, Inc.Direct Vet MarketingEuclises PharmaceuticalsIFM CinqueIFM ContinuaIFM QuattroIFM TreIkena Oncology, Inc.Morphic Holding, Inc.AavantgardebioAppcitoBicycle TherapeuticsCadent TherapeuticsCaptricityCogent BiosciencesDeliniaEthyreal BioF StarFlashnotesGeneration Bio (Alumni)Harbour AntibodiesInMojiKeasLTG Exam Prep PlatformMagenta TherapeuticsMicrometMnemosyne PharmaceuticalsMomenta PharmaceuticalsMomenta Pharmaceuticals, Inc. (Alumni)NovexelObsidian TherapeuticsOverdogPadlock TherapeuticsPheon TherapeuticsQuench BioRaze TherapeuticsRectifyReplimune Group, Inc. (Alumni)StromedixSurface OncologyTrace NeuroscienceTranslate BioTriplet TherapeuticsVitae Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 39
20 IPOs · 19 acquisitions · showing 32Q32 BioNASDAQ: QTTBSionna TherapeuticsNASDAQ: SIONEditas MedicineNASDAQ: EDITIntellia TherapeuticsNASDAQ: NTLAKALA BIONASDAQ: KALAKorro BioNASDAQ: KRRONeuroneticsNASDAQ: STIMSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLOAlnylam PharmaceuticalsNASDAQ: ALNYBicycleNASDAQ: BCYCDisc MedicineNASDAQ: IRONDyne TherapeuticsNASDAQ: DYNExelixisNASDAQ: EXELJohnson & JohnsonNYSE: JNJKymera TherapeuticsNASDAQ: KYMRmiRagen TherapeuticsNASDAQ: VRDNReplimuneNASDAQ: REPLSynlogicOTC: SYBXUnum TherapeuticsNASDAQ: COGTCadenttxacq. by NovartisCreative Marketacq. by DribbbleDeepscaleacq. by TeslaDeliniaacq. by CelgeneGrabCADacq. by StratasysHorizon Therapeuticsacq. by AmgenKinveyacq. by Progress SoftwareMorphoSysacq. by NovartisNxStage Medicalacq. by Fresenius Medical CareOverdogacq. by Odd NetworksTranslate Bioacq. by SanofiVigil Neuroscienceacq. by Sanofi
Portfolio news
latest coverage across their companiesQ32 Bio · stocktitan.net · Jul 15, 2026
Spero · stocktitan.net · Jul 14, 2026
Spero Therapeutics · stocktitan.net · Jul 14, 2026
Triveni · finsmes.com · Jun 17, 2026
Kinaset Therapeutics · finsmes.com · Jan 12, 2026
Lifordi Immunotherapeutics · finsmes.com · Nov 19, 2025
Affinia Therapeutics · finsmes.com · Oct 8, 2025
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Dyne Therapeutics | 18.9% | $28.00 | Jan 2021 | $273M |
| Replimune | 14.4% | $15.00 | Jul 2018 | $66.8M |
| Sionna Therapeutics | 8.5% | $18.00 | Feb 2025 | $65.4M |
| Spero Therapeutics | 5.7% | $12.50 | Jul 2018 | $12.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ1 insider ownership filing (Forms 3/4/5)
at Q32 Bio Inc. (QTTB)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Atlas Venture made?
- Atlas Venture has 169 tracked investments, 39 of which have exited, including 10 dated in the last 24 months.
- What stage does Atlas Venture invest at?
- Atlas Venture invests at the Seed, Series A, Series B stages.
- What is Atlas Venture's typical check size?
- Atlas Venture typically writes checks of $500K – $1M.
- What sectors does Atlas Venture focus on?
- Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Atlas Venture located?
- Atlas Venture is headquartered in Cambridge, US.
- Does Atlas Venture lead rounds?
- Atlas Venture typically participates in rounds rather than leading them.
- Who does Atlas Venture co-invest with?
- Atlas Venture most often shares deals with Sanofi Ventures, Bain Capital Life Sciences, Foresite Capital, among 80 tracked co-investors.
Co-investors · 127
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Accomplice is a venture capital firm that has backed early-stage companies across sectors, having been part of the origin stories of companies like AngelList, DraftKings, Patreon and WHOOP.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Lightspeed Venture Partners is a global venture capital firm that backs founders from Seed through Series F and beyond, emphasizing deep, immersive partnerships with the companies it invests in.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
▶115 more co-investors
Foresite CapitalAccess IndustriesLongwood FundNew Enterprise Associates (NEA)ForbionSR One Capital ManagementvenBio PartnersThird Rock VenturesSV Health InvestorsNextech InvestFounder CollectivePolaris PartnersSofinnova PartnersPivotal Life SciencesDigitalis VenturesHatteras Venture PartnersVida VenturesFirst Round CapitalMenlo VenturesCanaan PartnersLeaps by BayerAndreessen HorowitzBessemer Venture PartnersRedpoint VenturesDCVC (Data Collective)CRV (Charles River Ventures)Entrée CapitalEQT Life SciencesFounders Circle CapitalVivo CapitalJMI EquityBroadview VenturesSequoia CapitalAccelSV AngelBoxGroupACME CapitalSlow VenturesInnovation EndeavorsKapor CapitalCota CapitalStride VCAlleyCorpGE VenturesJohnson & Johnson Innovation – JJDCPillar VCMPM BioImpactAutotech VenturesNovartis Venture FundSignal Peak VenturesAndera PartnersYsios CapitalAdvent Life SciencesRoche Venture FundBorealis VenturesACORN BIOVENTURESSherpa VenturesAditum BioGeneral CatalystCraft VenturesGreylock PartnersIndex VenturesUncork CapitalFelicis VenturesDST GlobalFirstMark CapitalHCVCAME Cloud VenturesAccel-KKRPractical Venture CapitalCrosslink CapitalPoint NinePareto HoldingsEntrepreneur FirstGeneral AtlanticHV CapitalPassion CapitalWildcat Venture Partners83NorthPeakBreakthrough Energy VenturesFELIX CAPITALCapital FactoryWalden InternationalLocalGlobeMMC VenturesHoxton VenturesBlue Owl CapitalPlayground GlobalMotier VenturesNGP CapitalHighbury HoldingsBIOSPRING PARTNERS20VCIrishAngelsAngel InvestJigsaw VCMangrove Capital PartnersEpisode1Kima VenturesMotivate Venture CapitalDay One VenturesAllen Institute for Artificial Intelligence Incubator (AI2)AlbionVCHaatchKurma PartnersAxeleo CapitalBeyond CapitalNew Leaf Venture PartnersCornerstone VCJourney VenturesFortino CapitalIdinvest PartnersAltitude Ventures Management, LlcNest.Bio Ventures
Firms observed investing alongside Atlas Venture, from public investor directories. Shared companies are the overlap with Atlas Venture's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.